RxDoctor Payments Data

Prahlad Patel, MD

Internal Medicine · Sicklerville, NJNPI 1184705535

Payments from drug & device makers

$8,203in general payments, 2019–2025

Across 429 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$749
  • Abbott$471
  • Boehringer Ingelheim$265
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$8,178100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,203 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$162,661
Medicare patients
333
Services billed
2,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xigduo XrDapaglifloz Propaned/Metformin52$74,567
MounjaroTirzepatide56$65,900
JardianceEmpagliflozin53$65,404
EliquisApixaban51$62,621
FarxigaDapagliflozin Propanediol61$62,062
Janumet XrSitagliptin Phos/Metformin Hcl33$36,990
JanuviaSitagliptin Phosphate23$31,155
OzempicSemaglutide18$26,075
Synjardy XrEmpagliflozin/Metformin Hcl15$23,409
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$21,891
TradjentaLinagliptin19$20,051
TrulicityDulaglutide12$17,800
LinzessLinaclotide15$16,260
RybelsusSemaglutide13$14,288
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$13,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$265$108,86487 claims
Lilly USA, LLCMounjaro, Trulicity$194$83,70068 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,994$82,73594 claims
MerckJanumet Xr, Januvia$116$68,14556 claims
PfizerEliquis$53$62,62151 claims
Novo NordiskOzempic, Rybelsus$749$40,36331 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$1,182$32,76652 claims
AbbVieLinzess$1,679$16,26015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Sicklerville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →